Kyverna Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Kyverna Therapeutics, Inc. (KYTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 1.00 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-11
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 574.98K shares, a 34.23% decline year-over-year.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 428.18K shares, a 70.75% increase year-over-year.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 115.94K shares, a 66.68% decline year-over-year.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 98.37K shares, a 50.43% decline year-over-year.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.34M shares, a 102.71% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 660.66K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 574.98K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 1.00M shares 10-Q · filed 2026-08-11 | 1.12M shares derived: sum of 3 quarters · filed 2026-08-11 | 1.22M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 428.18K shares 10-Q · filed 2026-05-12 | 544.12K shares derived: sum of 2 quarters · filed 2026-05-12 | 642.49K shares derived: sum of 3 quarters · filed 2026-05-12 | 1.52M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 115.94K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 214.31K shares derived: sum of 2 quarters · filed 2026-03-26 | 1.09M shares derived: sum of 3 quarters · filed 2026-03-26 | 1.34M shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 98.37K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 972.55K shares derived: sum of 2 quarters · filed 2025-11-12 | 1.22M shares 10-Q · filed 2025-11-12 | 1.57M shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 874.18K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 1.12M shares 10-Q · filed 2025-08-12 | 1.47M shares derived: sum of 3 quarters · filed 2025-08-12 | 1.67M shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 250.77K shares 10-Q · filed 2025-05-13 | 598.69K shares derived: sum of 2 quarters · filed 2025-05-13 | 797.13K shares derived: sum of 3 quarters · filed 2025-05-13 | |
| 2024-12-31 | 347.93K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 546.37K shares derived: sum of 2 quarters · filed 2025-03-27 | 660.66K shares 10-K · filed 2025-03-27 | |
| 2024-09-30 | 198.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 312.74K shares 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | 114.30K shares 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |